Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
Eva Soler Espejo, Consultant Hematologist at Virgen de la Arrixaca University Clinical Hospital, shared a post on LinkedIn about a recent article she co-authored with her colleagues, adding:
”Anticoagulation in atrial fibrillation reduces risk — but does not eliminate it completely.
I am very pleased to share our latest publication in the Journal of the American Heart Association (JAHA).
In this prospective real-world study of anticoagulated patients with atrial fibrillation, we investigated whether the Atherogenic Index of Plasma (AIP) could help identify residual cardiovascular and thromboembolic risk.
Higher AIP levels were independently associated with worse clinical outcomes, particularly thromboembolic events and major adverse cardiovascular events (MACE), suggesting that this simple metabolic marker may provide incremental prognostic value beyond conventional risk assessment.
These findings underline the importance of better understanding residual risk in order to move towards more personalised and comprehensive management strategies in patients with AF.”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler‐Espejo, Yang Chen, José M. Rivera‐Caravaca, María P. Ramos‐Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on Journal of the American Heart Association
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS